WCG Partners with Veeva on IRB Document Transfer
WIRB-Copernicus (WCG) announced that it is partnering with Veeva Systems to improve the speed and accuracy of institutional review board (IRB) document transfer. WCG will build a seamless connection between WCG’s MyConnexus™ IRB document management web portal and Veeva Vault eTMF. By linking Vault eTMF with MyConnexus, IRB documentation can be automatically uploaded into the customer’s Vault eTMF to provide inspection-ready eTMF documents immediately, and reduce the possibility of human error during IRB document transfer.
Read the full release here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
